Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Biochim Biophys Acta. 2012 Aug 25;1833(4):823–832. doi: 10.1016/j.bbamcr.2012.08.012

New Insights Into the Functional Significance of the Acidic Region of the Unique N-Terminal Extension of Cardiac Troponin I

Marcus Henze a,, Stacey E Patrick a,, Aaron Hinken a, Sarah B Scruggs b, Paul Goldspink c, Pieter P de Tombe d, Minae Kobayashi a, Peipei Ping b, Tomoyoshi Kobayashi a, R John Solaro a,*
PMCID: PMC3548050  NIHMSID: NIHMS407371  PMID: 22940544

Abstract

Previous structural studies indicated a special functional role for an acidic region comprised of residues 1–10 in the unique N-terminal peptide of cardiac troponin I (cTnI). Employing LC-MS/MS, we determined the presence of phosphorylation sites at S5/S6 in cTnI from wild type mouse hearts as well as in hearts of mice chronically expressing active protein kinase C-ε (PKCε) and exhibiting severe dilated cardiomyopathy (DCM). To determine the functional significance of these phosphorylations, we cloned and expressed wild-type cTnI, (Wt), and cTnI variants expressing pseudo-phosphorylation cTnI-(S5D), cTnI(S6D), as well as cTnI(S5A) and cTnI(S6A). We exchanged native Tn of detergent-extracted (skinned) fiber bundles with Tn reconstituted with the variant cTnIs and measured tension and cross-bridge dynamics. Compared to controls, myofilaments controlled by cTnI with pseudo-phosphorylation (S6D) or Ala substitution (S6A) demonstrated a significant depression in maximum tension, ATPase rate, and ktr, but no change in half-maximally activating Ca2+. In contrast, pseudo-phosphorylation at position 5 (S5D) had no effects, although S5A induced an increase in Ca2+-sensitivity with no change in maximum tension or ktr. We further tested the impact of acidic domain modifications on myofilament function in studies examining the effects of cTnI(A2V), a mutation linked to DCM. This mutation significantly altered the inhibitory activity of cTnI as well cooperativity of activation of myofilament tension, but not when S23/S24 were pseudo-phosphorylated. Our data indicate a new functional and pathological role of amino acid modifications in the N-terminal acidic domain of cTnI that is modified by phosphorylations at cTnI(S23/S24).

Keywords: Cardiac, Ca-activation, phosphorylation, cardiomyopathy, thin filament

1. Introduction

In experiments reported here, we investigated the functional significance of modifications in an acidic region comprised of residues 1–10 in the unique N-terminal peptide of cardiac troponin I (cTnI). cTnI, in conjunction with the Ca-receptor, cardiac troponin C (cTnC), the scaffolding protein, cardiac troponin T (cTnT), and tropomyosin (Tm), functions in a molecular mechanism to switch on and modulate sarcomeric force and shortening [1, 2] In relaxed sarcomeres, two basic domains (an inhibitory peptide, Ip, and a second actin binding region [3, 4]) of cTnI are tethered to actin and together with the N-terminal extension of cTnT, hold Tm in a position to block force generating cross-bridges from reacting with thin filament actins. The actin-binding domains of cTnI flank a switch peptide (SwP) that binds to cTnC upon Ca-binding to its regulatory site [5, 6]. This movement of SwP induces a relocation of the cTnI interaction with actin thereby inducing a release of Tm from its blocking position and the thin filament from inhibition.

Unique domains, especially the cTnI N-terminus consisting of ~30 amino acids are well known to control cardiac function [710]. Phosphorylation at S23/S24, which are substrates for several protein kinases, especially protein kinase A (PKA) [11], depresses Ca-responsiveness of myofilament tension [2], increases the rate of myosin head binding to thin filaments[12], and increases in thin filament sliding velocity in the motility assay [13], but has no effect on maximum tension or open and closed states of the thin filaments [12]. There are also highly conserved serial Ser residues at position 5 and 6 in cTnI, but the significance of these residues has yet to be determined.

Results of recent studies have significantly altered thinking regarding the role of the unique N-terminus in control of cardiac function [7, 14, 15] The N-terminus did not resolve in the elucidation of the core crystal structure of cTnI [16], but Howarth et al. [14] determined the NMR solution structure of cTnI (aa 1–32) and employed bioinformatic analysis together with data from small angle x-ray scattering experiments to model the N-terminal extension into the core crystal structure of cTn. In the non-phosphorylated state, the model demonstrated a close interaction between the N-terminal extension with cTnC near L29 as previously shown in peptide-array experiments [13]. The NMR solution structure also determined that upon phosphorylation of S23/S24, cTnI undergoes a major conformational transition dependent on a hinge within cTnI-(aa 33–42). Molecular docking of cTnI into the core structure indicated that this structural transition induced close proximity between acidic residues in the N-terminal extension (D3, E4, D7 and E11) with basic residues in the inhibitory peptide and with the SwP. The acidic region (aa 1–10) at the N-terminus, which is connected to the region housing S23/S24 by an extended poly-Pro II helix (aa 11–19), thus appeared to have a previously unappreciated functional significance based on an intra-molecular interaction [7, 17]. We [15] tested this idea by engineering a Cys residue into cTnI at positions 5 and 19 and demonstrated cross-linking of these sites to Met residues in the SwP of cTnI.

Following investigation of phosphorylation sites in mouse cTnI employing liquid chromatography with tandem mass spectrometry (LC-MS/MS), we discovered, as reported here, the presence of novel phosphorylation sites at S5/S6 of cTnI. At the same time there have been reports of the existence of these sites in human cTnI with evidence that the relative phosphorylation at these sites decreases with cardiac disorders such as dilated and hypertrophic cardiomyopathies [18, 19]. To determine the significance of phosphorylation in the unique N-terminus of cTnI at either S5 or S6, we expressed cTnI pseudo-phosphorylated at these sites, and determined their functional effects when exchanged into detergent-extracted (skinned) fiber bundles. To further investigate the significance of the acidic region of the cTnI N-terminus, we also expressed cTnI(A2V), a mutant linked to DCM, and determined its effects on myofilament function [20]. Our results indicate that phosphorylation and structural modifications depress myofilament tension and that the A2V mutation alters myofilament cooperative activation as well as responsiveness to phosphorylation of cTnI at S23/S24.

2. Methods

2.1 Animal model of dilated cardiomyopathy

Experiments using transgenic animals were conducted in accordance with the Institutional Animal Care and Use Committee at the University of Illinois and the National Institute of Health guidelines. PKCε transgenic mice were generated via cardiac-specific expression of constitutively active PKCε(A159E), driven by mouse α-myosin heavy chain promoter on a FVB background as previously described [21].

2.2 Protein purification and reconstitution into Tn complex and regulated myofilaments

We expressed and purified recombinant mouse and human cTnI (wild-type and variants as described in the results) employing pET3d, mouse cTnT containing an N-terminal myc tag in pSBET, and mouse and human cTnC in pET3d purified as described previously [2224]. Tn complex containing mouse cTnI, cTnT, and cTnC was used in S5/6 experiments, while the complex containing human cTnI with mouse cTnT and cTnC was used in the A2V experiments. Tn complex was reconstituted and verified as previously described [23,25,26]. Actin was isolated from rabbit fast skeletal muscle acetone powder and tropomyosin was prepared from bovine cardiac ether powder as described previously [26]. Myosin-S1 was made by chymotryptic digestion of rabbit psoas muscle myosin [23].

2.3 Mass spectrometry

Sarcomeric fractions were enriched from ventricular lysates of 12-month PKCε and FVB mice according to Scruggs et al. [27]. As a preparatory step to enrich endogenous cTnI prior to mass spectrometry, sarcomeric proteins (1 mg) were separated in solution via OFFGEL electrophoresis (Agilent Technologies) using a 24 cm, pH 7–10 IPG strip (Biorad) and the following focusing conditions: 8000 V, 64 kVh, 50 μA and 200 mW. To further enrich cTnI, OFFGEL fractions containing cTnI were separated via 12% SDS-PAGE. cTnI protein bands were excised and digested according to Deng et. al. [28]. LC-MS/MS with collision-induced dissociation (CID) fragmentation was performed on a linear trap quadrupole (LTQ) instrument (ThermoFisher Scientific) integrated with a Surveyor nano-LC instrument. A PicoFrit C18 column (75 μm x 10 cm, New Objective) containing resin (Biobasic C18, 5 μm particle size, 300-Å pore size, New Objective) was used. Electrospray ionization (ESI) conditions for the LTQ were 190 °C capillary temperature, 2.0 kV spray voltage, and a nano-LC source. Reverse-phase chromatography flow rate was 5 μl/min for loading and 220 nl/min for separation (buffer A: 0.1% formic acid, 2% acetonitrile; buffer B: 0.1% formic acid, 80% acetonitrile). Peptides were resolved as follows: time 0 min/2% B, time 100 min/50% B, time 110 min/100% B, time 120 min/100% B; time 121 min/2% B. The LTQ was operated in data-dependent mode; one full MS scan was followed by five MS2 scans. Spectra were searched against the International Protein Index mouse database (Version 3.47) using the Sequest algorithm (Bioworks Version 3.3). Search parameters were set as follows: partial enzymatic digestion (trypsin); two missed cleavages; 2.0 precursor tolerance; 1.0 fragment tolerance; fixed modification of cysteine carbamidomethylation (+57 Da); and variable modifications of methionine oxidation (+16 Da) and serine, threonine, and tyrosine phosphorylation (+80 Da). Identified peptides were filtered according to the following criteria: Xcorr >2.5 (+2) or >3.5 (+3). The reported peptides had a probability better than 95% (p < 0.05) in Scaffold. Phosphorylation site(s) were identified in two biological replicates.

2.4 Exchange of recombinant cTn into skinned left ventricular fiber bundles

In studies of pseudo-phosphorylation and related variants of cTnI(S5/S6), left ventricular papillary fiber bundles were freshly dissected from male FVBN mouse hearts, aged 4–5 months, in dissecting solution containing 100 mM BES, 10 mM EGTA, 6.57 mM MgCl2, 10 mM creatine phosphate, 6.22 mM ATP, 2.5 μM pepstatin, 1 μM leupeptin, 50 μM PMSF, 5 mM NaN3, pH 7.0. Whole papillary fiber bundles were then cut into strips 125–275 μm wide by 125–275 μm deep and incubated in the above solution containing 1% Triton X-100 at 4°C for 2 hours to allow complete skinning. Aluminum T-clips were attached to both ends of the fiber preparations following exchange of endogenous cTn for exogenous cTn. Fibers were exchanged by overnight incubation at 4°C in exchange buffer (200 mM KCl, 5 mM MgCl2, 5 mM EGTA, 20 mM MOPS, 1 mM DTT, pH 6.5) containing 12–15 μM recombinant cTn (containing mouse cTnI), as previously described [24]. A similar procedure using recombinant Tn complex (containing human cTnI) was carried out in studies of the cTnI(A2V) mutant and related variants described in the results section with the exception that female CD-1 mouse hearts aged 4–5 months were used. Recombinant cTn complexes containing N-terminal myc-tagged mouse cTnT were used in the present study to allow for the quantification of cTn exchange by Western blotting techniques as previously described [24]. Previous studies have demonstrated that myofilament function is not affected by the presence of the myc-tag [22,24].

2.5 Measurement of isometric tension, stiffness, ATPase, and ktr

Isometric tension and ATPase rate of skinned left ventricular fiber bundles were simultaneously measured using experimental apparatus and methodology according to de Tombe and Steinen as described in detail previously [29]. After mounting the fibers, one cycle of activation was performed and the sarcomere length was adjusted to 2.2 μm using diffraction by He-Ne laser following the procedures described by de Tombe and ter Keurs [30]. Sarcomere length remained stable throughout the experimental protocol. Measurements of the rate of force redevelopment (ktr) were carried out by a procedure originated by Brenner and Eisenberg [31]. Other aspects of the procedure were as described in detail by Chandra et. al. [22]. The fiber bundle was moved sequentially into relaxing solution, then into the pre-activating solution, and finally into the experimental pCa solution where isometric force, stiffness, ATPase, and ktr were determined. After these parameters were measured, the fiber was returned to the relaxing solution until force decreased to the pre-activation level, followed by placement into the pre-activating solution in preparation for the next activation. Each fiber bundle underwent 8–10 contractions, with the first and last contractions being in maximal activating solution, pCa 4.5. Fibers were discarded if tension decreased by greater than 25% of the initial activation. Steady-state ATPase rate was determined by an enzyme-coupled ultraviolet light absorbance assay previously described, in which ATP consumed by the muscle during contraction was stoichiometrically linked to NAD+ formation. Calibration curves were performed with each experimental contraction as previously described [29]. The rate of force redevelopment, ktr, was measured in each pCa solution by a protocol previously described by Hinken and McDonald [32]. All mechanical experiments were performed at either 15° (A2V experiments) or 20° C (S5/6 experiments). Following mechanical measurements, each fiber was stored at −80° C for subsequent biochemical analysis.

2.6 In-vitro PKA phosphorylation

Purified cTn containing Wt, S6A, and S6D TnI variants were incubated with 2.5 mM ATP for 30 min at 27° C in 0.2 M KCl, 5 mM EGTA, 5 mM MgCl2, 20 mM MOPS, 1 mM DTT, pH 6.5 or in the above solution and 0.025 U PKA (Sigma)/ug TnI. PKA treated and untreated cTn complexes were dialized overnight in 0.1 M NaCl, 5 mM MgCl2, 0.1 mM CaCl2, 20 mM Tris, pH 8.0 prior to use in in-vitro ATPase assay as described below. Phosphorylation of cTnI was confirmed in samples by 12% SDS-PAGE using ProQ Diamond stain (Invitrogen).

2.7 ATPase assay with reconstituted myofilaments

In vitro ATPase assay was performed as described previously [33]. Myofilaments were reconstituted using cTn complex containing PKA treated and untreated cTnI (Wt, S6D, S6A), myosin S1, actin, and tropomyosin and were dialized against 70 mM NaCl, 10 mM MgCl2, 40 mM MOPS, pH 7.0. Assay conditions contained 5 μM actin, 0.4 μM tropomyosin, 0.2 μM S1, and 1 mM ATP with various concentrations of cTn complex with a total reaction concentration of 35 mM NaCl, 5 mM MgCl2, 20 mM MOPS, pH 7.0. Reactions were performed in the presence of Ca2+ (0.1 mM) or in its absence (2 mM EGTA), incubated at 27° C, and were quenched in 0.2 M perchloric acid at 10° C at various times. Phosphate production was measured following incubation for 20 min at 27° C with a malachite green assay [33,34] by spectrophotometric absorbance at 655 nm. In studies with the cTnI (A2V) mutant and related variants, the reaction mixture were the same as described above except that actin, Tm, and myosin S-1 concentrations were 6, 1, and 0.5 μM respectively. ATPase was determined as described above at 25° C.

2.8 Solutions

Relaxing solution (pCa 10.0), contained 100 mM BES, 1 mM free Mg2+, 5 mM MgATP, 10 mM EGTA, 48.95 mM potassium propionate, and 1mM DTT. Pre-activating solution contained 100 mM BES, 1 mM free Mg2+, 5 mM MgATP, 0.50 mM EGTA, 9.50 mM HDTA, 49.19 mM potassium propionate, and 1 mM DTT. Maximal activating solution (pCa 4.5), contained 75 mM BES, 1 mM free Mg2+, 5 mM MgATP, 10.00 mM EGTA, 10.01 mM CaCl2, 29.06 mM potassium propionate, and 1 mM DTT. Pyruvate kinase and lactate dehydrogenase were added to all three solutions prior to use at final concentrations of 1 mg/ml and 0.1 mg/ml, respectively. Relaxing solution and maximal activating solutions were then mixed to create experimental pCa solutions ranging from pCa 6.4 to 4.5. All solutions had a final ionic strength of 180 mM and pH 7.0 at 20° C. Solution compositions were calculated by customized software based upon binding constants described previously [35].

2.9 Data and Statistical analysis

Tension-, stiffness, ATPase-, and ktr-pCa relationships were fit with a modified four parameter Hill equation: P = Po + axb/(cb + xb), where P is the parameter of interest (tension, ATPase, ktr); Po is the minimum value, a is the maximum value minus Po; x is pCa; b is −e (Hill coefficient); and c is the pCa at which 50% of maximum value is reached (pCa50). ATPase-tension, stiffness-tension, and ktr -relative tension (P/Po) relationships were fit with linear curves. All values are presented as mean ± standard error of mean (SEM). Data were analyzed using 2-way ANOVA, a Student-Newman-Keuls post hoc method, with a level of statistical significance set at P< 0.05.

3. Results

3.1 Identification of the cTnI S5/S6 Phosphorylation Site via LC-MS/MS

To identify novel sites of cTnI phosphorylation in mouse myocardium that potentially play a role in the maladaptive functional response, sarcomeric sub-proteomes were analyzed via LC-MS/MS. A triply-charged precursor ion (m/z 649.5) corresponding to singly-phosphorylated cTnI peptide (aa 2–20) was identified, and upon fragmentation with CID, the phospho-site was identified as either S5 or S6 (Figure 1). This site represents a novel phosphorylation site on the unique mouse cardiac N-terminus of cTnI. S5/S6 phosphorylation was identified in both wild type and in mice expressing active PKCε.

Figure 1. Identification of a novel phosphorylation site in cTnI.

Figure 1

cTnI from Wt mice were digested and analyzed via LC-MS/MS on an LTQ mass spectrometer. CID fragmentation spectra from both wild type (A) and PKCε (B) show a triply-charged, singly-phosphorylated precursor ion (m/z 649.5), which localizes the phosphorylation to either Ser-5 or Ser-6 in the (ambiguity denoted by the parentheses). Observed a-, b- and y-ions with a relative abundance above 5% are labeled above each corresponding ion in the spectrum and are illustrated in the peptide sequence (top). Essentially identical results were obtain from heart samples from mice expressing acitive PKCε.

3.2 Chemo-mechanical Measurements in Skinned Fiber Bundles Regulated by Control and Pseudo-phosphorylated cTnI

In order to determine the functional role of phosphorylation at S5 and S6 of mouse cTnI, we designed recombinant cTn complexes and exchanged them with endogenous cTn from skinned mouse papillary muscle fibers. Serine 5 and 6 of cTnI were pseudo-phosphorylated by substitution with aspartic acid (S5D and S6D, respectively). Non-phosphorylatable cTnI variants were generated by substitution of alanine for serine 5 and 6 (S5A and S6A, respectively). Recombinant cTnI proteins were incorporated into cTn complex containing myc-tagged mouse cardiac TnT (myc-cTnT) and mouse cardiac cTnC. Wild-type (Wt) and variant cTn complexes were then exchanged into skinned mouse papillary muscle fibers. As illustrated in Figure 2, this method resulted in an average exchange efficiency of 33–61% as measured by Western Blot using cTnT-specific antibody. Exchange efficiency was determined as the ratio of the slower migrating cTnT (myc-cTnT) to total cTnT (endogenous + myc-cTnT (Figure 2)). There was variability in exchange efficiency, but the variability was not reflected in our measurements of tension, ATPase activity, or stiffness, which demonstrated relatively small standard deviations (Figures 3, 4).

Figure 2. Quantification of cTn exchange in skinned fiber bundles.

Figure 2

The exchange of endogenous for exogenous Wt or mutant cTn was determined by Western blot analysis from skinned fiber samples using the cTnT-specific monoclonal antibody CT3. The difference in migration of endogenous cTnT and exogenous myc-tagged cTnT (myc-cTnT) allowed for the determination of the efficiency of exchange. Top: Representative non-exchanged fibers (NE) and an exchanged fiber (Ex). Bottom: Representative blot of individual exchanged fibers (Wt: lanes 3,9; S5D: lanes 4,8,10; S5A: lane 5; S6D: lane 6; S6A: lane 7) and recombinant cTn complex (Control: lanes 1,2).

Figure 3. Tension- and ATPase-pCa relation in skinned fiber bundles exchanged with Wt or mutant cTn.

Figure 3

Tension-pCa relationship (A). ATPase-pCa relationship (B). Tension cost (C). Tension- and ATPase-pCa relationships are presented as mean ± SEM. n = 8–10 fibers, N=3–4 hearts. Tension cost is presented as the linear regression of mean data from A and B.

Figure 4. Stiffness-pCa relation in skinned fiber bundles exchanged with Wt or mutant cTn.

Figure 4

Stiffness-pCa relationship (A). Stiffness-tension relationship (B). Stiffness-pCa relationships is presented as mean ± SEM. n = 8–10 fibers, N = 3–4 hearts. Stiffness-tension relationship is presented as the linear regression of mean data from A and Figure 3A.

The functional effects of cTnI variants were determined by simultaneously measuring tension, ATPase activity, and ktr over a range of pCa values. The pCa-tension relation revealed a significant decrease in maximum tension in cTnI-S5A, -S6D, and -S6A-exchanged fibers compared to Wt-exchanged fibers (Wt: Fmax=20.30 ± 1.60 mN/mm2; S5A: Fmax=15.25 ± 0.84 mN/mm2, P<0.01; S6A: Fmax=11.34 ± 0.37 mN/mm2, P<0.01; S6D: Fmax=11.90 ± 0.61 mN/mm2, P<0.01; Figure 3A), with no significant effect of S5D. The pCa-tension relation showed increased Ca2+ sensitivity in the S5A-exchanged mutant compared to Wt-exchanged fibers (Wt: pCa50=5.76 ± 0.04; S5A: pCa50=5.93 ± 0.04, P<0.01), with no significant effect of either S6A or S6D. There were no effects of any of the mutations on the Hill coefficient of the pCa-tension relationship.

ATPase activity was measured at each pCa value via the rate of decreasing UV absorption at 310 nm within the pCa solution during tension development as described under “Materials and Methods”. The resulting pCa-ATPase activity relation (Figure 3B) showed decreased maximum ATPase activity in S5A-, S6A-, and S6D-exchanged fibers compared to Wt-exchanged fibers (Wt: 183.2 ± 4.7 pmol/s/mm3; S5A: 152.5 ± 3.3 pmol/s/mm3, P<0.05; S6A: 136.7 ± 3.4 pmol/s/mm3, P<0.01; S6D: 135.3 ± 3.1 pmol/s/mm3, P<0.01). The relationship between ATPase and tension (tension cost) showed no differences among any of the variant- and Wt-exchanged fibers (Figure 3C), indicating no effect of any of the cTnI modifications on steady-state rate of cross-bridge detachment. The pCa-ATPase activity relation demonstrated a significant decrease in the Hill coefficient in S6A- and S6D-exchanged fibers compared to Wt-exchanged fibers (Wt: nH=3.14 ± 0.35; S6A: nH=1.22 ± 0.08, P<0.05; S6D: nH=1.10 ± 0.08, P<0.05). There was no effect of any of the variants on pCa50 of ATPase activity.

As summarized in the data shown in Figure 4, the pCa-stiffness relationship showed a decrease in maximal stiffness in S5A-, S6A-, and S6D-exchanged fibers compared to Wt-exchanged fibers (Wt: 26.12 ± 0.65; S5A: 19.94 ± 0.45 arbitrary units (au), P<0.05, S6A: 16.14 ± 0.51 au, P<0.01; S6D: 17.13 ± 0.54 au, P<0.01, Figure 4A). The decreased tension and stiffness of S5A-, S6A-, and S6D-exchanged fibers resulted in a normal stiffness to tension ratio, indicating no effect of either mutation on the force generated per cross-bridge (Figure 4B). The pCa-stiffness relation also showed a decreased Hill coefficient with the S6A and S6D mutants compared to Wt (S6A: nH=1.15 ± 0.11; S6D: nH=1.08 ± 0.11; Wt: nH=3.06 ± 0.32).

At steady state for each pCa value, fibers were subjected to a rapid release re-stretch maneuver, resulting in disengagement of attached cross-bridges. The measure of ktr reflects the sum of the rate-limiting transition steps (ktr = f + g) of myosin cross-bridges to and from the strongly-bound, force-generating state during isometric contraction. We found ktr to be dependent on the pCa as previously reported [36,37]. As recommended by Patel et al. [36], we expressed the rate of force redevelopment as a function of relative isometric tension. Ktr was quantified at each pCa value by use of a single-exponential equation and plotted versus the percent of maximal tension (P/Po) to generate a linear relationship (Figure 5A). The S6A and S6D mutations showed a decreased slope of the ktr-P/Po relation compared to Wt (Wt: 16.65 ± 1.44 s−1; S6A: 9.45 ± 0.95 s−1, P<0.01, S6D: 9.03 ± 1.13 s−1, P<0.01), Figure 5B), indicating decreased number of cross-bridges entering into force generating states in these variants.

Figure 5. Ktr-relative tension relationship in skinned fiber bundles exchanged with Wt or mutant cTn.

Figure 5

Average ktr-relative tension plots from each experimental group (A). Slope of ktr-relative tension between fibers exchanged with Wt and mutant cTn (B). Ktr-relative tension are presented as the linear relationship of ktr and relative tension. Slope of ktr-relative tension relationships are presented as mean ± SEM (B). n = 5–10 fibers, N = 3–4 hearts. **P<0.01 compared to Wt.

3.3 In vitro studies on control of reconstituted myofilaments by cTnI-S5/6 variants

Data presented so far indicate that modifications at S6 significantly inhibit the actin-cross-bridge reaction. To address the mechanism of this modification, we performed a series of experiments testing whether modifications at S6 affect the ability of cTnI to inhibit the actin-cross-bridge reaction. Data in Figure 6A show that neither S6A nor S6D influenced the ability of cTnI to inhibit actin-myosin interactions. This fits with our finding that the influence of modifications at S6 alters the Ca-activated state of the myofilaments. To examine this possibility further, we investigated the influence of the modifications at S6 on the ability of cTn to confer activation of the myofilaments in the presence of Ca2+. In this same series we also tested for interactions between cTnI-S6 variants and S23/S24, which are substrates for PKA [9]. Data shown in Figure 6B demonstrate cTnI-specific phosphorylation, as determined by ProQ analysis, showing no difference in the amount of cTnI phosphorylation between groups. Data illustrated in Figure 6C show the results of ATPase measurements from reconstituted myofilament preparations regulated with increasing concentrations of either control or S6 cTn, with and without PKA-treatment. In Figure 6C, the solid line shows the relation between untreated cTn containing TnI-WT, -S6D, or -S6A and ATPase rate, while the dashed lines show the relation of these cTn complexes with ATPase rate following PKA-treatment. In the presence of Ca2+, cTn complex containing TnI-S6D at 0.5 μM Tn (1:10 molar ratio of Tm:actin) showed decreased ATPase activity compared to TnI-Wt reconstituted myofilaments (0.14 ± 0.02 vs. 0.29 ± 0.02 s−1, P<0.01, Figure 6C). There was no difference between the ATPase activity of preparations controlled by either cTn-TnI-S6A or cTn-TnI-Wt at any concentration tested. In the absence of Ca2+, there was no difference in ATPase activity between myofilaments reconstituted with cTn containing either S6 variant or Wt cTnI (grey lines, Figure 6C). Treatment of TnI-Wt with PKA prior to incorporation into Tn complex showed significant inhibition of ATPase activity compared to untreated cTn-TnI-Wt myofilaments ([Tn]=1.0 μM: 0.04 ± 0.01 vs. 0.36 ± 0.04 s−1, P<0.01). Troponin complex containing PKA-phosphorylated TnI-S6D or -S6A also showed PKA-induced inhibition of ATPase activity compared to their respective untreated groups ([Tn]=1.0 μM; S6D: 0.10 ± 0.01 vs. 0.32 ± 0.02 s−1, P<0.01, S6A: 0.15 ± 0.022 vs. 0.44 ± 0.02 s−1, P<0.01). However, PKA-treatment had a reduced effect on inhibiting ATPase activity in Tn containing TnI-S6 variants compared to PKA-treated TnI-Wt ([Tn]=1.0 μM; S6D: 0.10 ± 0.01 vs. 0.04 ± 0.01 s−1, S6A: 0.15 ± 0.02 vs. 0.04 ± 0.01 s-1, P<0.05).

Figure 6. Wt- and mutant-cTn effects on actin-Tm-S1 ATPase activity.

Figure 6

All assays contained 7 μM actin, 0.4 μM tropomyosin and 0.2 μM myosin S1, with final buffer conditions of 35 mM NaCl, 5 mM MgCl2, and 20 mM MOPS, pH 7.0. Wt- and mutant cTnI inhibition of ATPase activity (A). Wt- and mutant-cTn effects on ATPase activity in the presence (black lines) and absence (grey lines) of Ca2+ (C). Relative PKA-dependant phosphorylation of TnI between Wt, S6A, and S6D Tn complexes (B). ATPase activity was calculated by subtracting the ATPase activity of myosin S1 only at each concentration. Data presented as mean ± SEM. n = 3–4. **P<0.01.

3.4 An A2V mutation in the acidic region of cTnI and linked to dilated cardiomyopathy has altered binding to thin filaments and to cTnC

In view of data demonstrating the potential of the acidic region of cTnI to influence myofilament function via structural and charge changes, we sought to determine whether other significant modifications in this region might affect myofilament function. We focused on an A2V mutation linked to DCM in order to provide more support for the significance of these cTnI residues. Murphy et. al., [20] reported that the A2V mutation caused a significant impairment in the interaction between cTnI and cTnT using a heterologous cell system. However, virtually nothing is known about whether and how this mutation alters myofilament regulation or the response to β-adrenergic stimulation. We therefore determined the functional effects of the cTnI A2V mutation on myofilament regulation and myofilament response to PKA phosphorylation. To determine the effects of the A2V mutation and PKA pseudo-phosphorylation (S23D/S24D) on cTnI inhibitory activity, we measured actin-Tm-S1 ATPase activity as a function of cTnI concentration in the absence of Ca2+. Figure 7A shows averaged percent maximum ATPase activity for each form of cTnI. Maximum inhibition occurred near a 1:1 actin:TnI ratio, but the extent of inhibition was significantly less for cTnI-A2V as compared to Wt at all concentrations studied (all concentrations P<0.05, Figure 7A). Alone, cTnI-S23D/S24D demonstrated the same inhibition as Wt, which was also similar to the inhibition by cTnI-A2V/S23D/S24D. The lower inhibitory activity of cTnI-A2V was restored to that of Wt by pseudo-phosphorylation at S23/S24.

Figure 7. Wt- and mutant-cTn effects on actin-Tm-S1 ATPase activity.

Figure 7

Wt and mutant cTnI inhibition of ATPase activity (A). All assays contained 6 μM actin, 1 μM tropomyosin and 0.5 μM myosin S1, with final buffer conditions of 10 mM NaCl, 5 mM MgCl2, and 20 mM MOPS, pH 7.0. Wt- and mutant cTnI inhibition of ATPase activity (A). Effects of increasing ratio of cTnC to Wt- and mutant cTnI- on ATPase activity in the presence of Ca2+ (pCa 4.0). Percent maximal ATPase activity was calculated by subtracting the ATPase activity of myosin S1 only and dividing by ATPase activity at zero cTnI (Figure 7A) and at zero cTnC (Figure 7B). Data presented as mean ± SEM. n = 4–6. *P<0.05.

We measured ATPase activity as a function of TnC:TnI ratio to determine the effects of the A2V mutation and PKA pseudo-phosphorylation on the Ca-TnC as a method to probe the Ca-dependent cTnC-cTnI interactions. Figure 7B shows averaged percent maximum ATPase activities at pCa 4.5 as a function of varying molar ratios of cTnC:cTnI. Myofilaments controlled by either Wt or cTnI-S23D/S24D showed a similar increase in ATPase rate with increasing molar ratios of cTnC:cTnI. However, compared to these controls, the ability of cTnC to reverse inhibition by cTnI-A2V was significantly depressed (all concentrations P<0.05, Figure 7B). Moreover, at all ratios, cTnC reversed inhibition by cTnI-A2V/S23D/S24D to a lower extent than cTnI-A2V (all concentrations P<0.05). These results indicate that in this assay the A2V mutation decreases the affinity of the TnI regulatory region for TnC, and PKA pseudo-phosphorylation further decreases the affinity in the presence of the A2V mutation.

3.5 Myofilaments regulated by cTn-A2V demonstrate altered cooperativity and kinetics of force redevelopment (ktr) dependent on pseudo-phosphorylation of S23/S24

To determine the effects of the A2V mutation and PKA pseudo-phosphorylation on myofilament mechanical properties, we exchanged Tn containing cTnI-Wt, A2V, S23D/S24D, and A2V/S23D/S24D into skinned left ventricular papillary fiber bundles. Data in Figure 8 show tension-pCa relations from each group and demonstrate that Ca2+ sensitivity (pCa50) of steady state tension and maximum tension of skinned fiber bundles regulated by cTnI-A2V were the same as the controls (Wt: Fmax=26.7 ± 0.9 mN/mm2; A2V: Fmax=23.0 ± 1.5 mN/mm2; Wt: pCa50=5.71 ± 0.02; A2V: pCa50=5.70 ± 0.02, Figure 8A).. However, in fibers regulated by the cTnI-A2V mutation alone, there was a significantly decreased Hill coefficient (nH), a measure of the cooperativity of tension activation (Wt: nH=4.18 ± 0.10; A2V: nH= 3.77 ± 0.10, P<0.01). cTnI-S23D/S24D caused a significant desensitization of the tension-pCa relation as previously demonstrated [38] in the presence or absence of the A2V mutation (Wt: pCa50=5.71 ± 0.02; S23D/S24D: pCa50=5.55 ± 0.02, P<0.01; A2V/S23D/S24D: pCa50=5.53 ± 0.03, P<0.01), with no effect on maximum tension or nH.

Figure 8. Tension- and ATPase-pCa relation in skinned fiber bundles exchanged with Wt or mutant cTn containing cTnI-A2V.

Figure 8

Tension-pCa relationship (A). ATPase-pCa relationship (B). Tension cost (C). Tension- and ATPase-pCa relationships are presented as mean ± SEM. n = 11–19 fibers, N=4–8 hearts. Tension cost is presented as the linear regression of mean data from A and B.

Figure 8B shows results of experiments in which we determined ATPase rate of the skinned fiber bundles. We found that in fibers controlled by cTnI-A2V there was no effect on the Ca2+ sensitivity of ATPase activity, the Hill coefficient of the ATPase activity-pCa relation, or the maximum ATPase activity. Pseudo-phosphorylation, whether in the absence or presence of the cTnI-A2V mutation, induced a rightward shift of the ATPase activity-pCa relation when compared to Wt (Wt: pCa50=5.70 ± 0.02; S23D/S24D: pCa50=5.55 ± 0.03, P<0.01; A2V/S23D/S24D: pCa50=5.54 ± 0.03, P<0.01), consistent with previous studies, but did not significantly alter other parameters. We also analyzed the ATPase activity-tension relation, or tension cost (Figure 8C). We found that the cTnI-A2V mutation alone did not alter the relation compared to Wt (Wt: 5.15 ± 0.21; A2V: 5.25 ± 0.40). In contrast, cTnI-S23D/S24D and cTnI-A2V/S23D/S24D exhibited significantly higher tension costs than their counterparts (Wt: 5.15 ± 0.21; S23D/S24D: 6.18 ± 0.48, P<0.01; A2V/S23D/S24D: 6.68 ± 0.47, P<0.01). These results indicate that PKA pseudo-phosphorylation increases the rate of cross-bridge detachment, which has previously been reported [38].

To further investigate rate constants for the cross-bridge reactions, we measured ktr as function of pCa and of relative tension. Figure 9A depicts representative ktr -relative tension relations for each group and shows that the cTnI-A2V mutation significantly decreased the slope (Wt: 8.39 ± 0.50; A2V: 6.82 ± 0.50, P<0.01, Figure 9B) and significantly increased the y-intercept of the relationship (Wt: 3.91 ± 0.31; A2V: 5.67 ± 0.58, P<0.01) as compared to Wt, whereas both PKA pseudo- phosphorylation variants were similar to Wt. These results indicate that the A2V mutation increases the kinetics of force redevelopment at sub-maximal, but not maximal Ca2+ levels.

Figure 9. Ktr-relative tension relationship in skinned fiber bundles exchanged with Wt or mutant cTn containing cTnI-A2V.

Figure 9

Average ktr-relative tension plots from each experimental group (A). Slope of ktr-relative tension between fibers exchanged with Wt and mutant cTn (B). Ktr-relative tension are presented as the linear relationship of ktr and relative tension. Slope of ktr-relative tension relationships are presented as mean ± SEM (B). n = 5–8 fibers, N = 3–5 hearts. *P<0.01 compared to Wt.

4. Discussion

Our results provide the first evidence of a functional significance of conformational changes and novel sites of phosphorylation at the acidic region of the unique N-terminus of cTnI. Our findings also extend understanding of potential control of cardiac function by the N-terminus of cTnI physiological and patho-physiological states. It is apparent from our results that these conformational and charge induced modulations are potentially significant factors in acquired and familial cardiomyopathies. While carrying out the present studies, we became aware of a report by Zhang et al. [19] identifying cTnI-S5/S6 in human myocardium and demonstrating a decrease in phosphorylation of these sites in samples from hearts in failure. However, no functional significance of these sites was assigned in this study. In view of our data showing a depression in maximum tension with S6D substitution (Figure 3A), decreased phosphorylation of this site in human heart failure may be compensatory. Our studies involving LC-MS/MS identified the Ser-5/-6 in both wild type and the PKCε over-expressing mouse model, a known model of DCM [21]. The development of DCM in these mice has been attributed to decreased Ca-sensitivity, most notably through phosphorylation of cTnI at S43/S45 and T144 [39,40]. Modification at these sites depresses myofilament response to Ca2+ and maximum tension development [39]. Although the kinases involved in modification of these novel sites are unknown, bioinformatic analysis of cTnI (NetPhosK, Technical University of Denmark) shows a relatively high score for the involvement of Ca/calmodulin-dependant kinase II (CaMKII) (Ser-5: 0.58 and Ser-6: 0.61). However, to determine whether phosphorylation levels at cTnI-S5/S6 are different in PKCε over-expressing hearts, as well as the kinase or kinases responsible for phosphorylation of these sites requires future quantitative analysis.

Our data demonstrate that pseudo-phosphorylation of cTnI-S6 in the acidic domain of the N-terminus induces a depressed maximum tension development of skinned fiber preparations with no apparent change in the stiffness/tension ratio or cross-bridge detachment rate, but a reduction in the number of cross-bridges entering into force generating states. The particular sensitivity of activation of tension to modification of cTnI-S6 is emphasized by our data demonstrating little or no effects of cTnI-S5D or cTnI-S5A, but significant effects cTnI-S6D and cTnI-S6A. We think that the mechanism for these effects may involve an intra-molecular interaction, as described above, between the acidic region containing cTnI-S6, and regulatory domains surrounding the Ip of cTnI. Our proposal is that when cTnI-S6 is phosphorylated or conformationally modified, the interaction of the SwP and the acidic region of cTnI impedes release of the SwP/Ip region from actin, and therefore induces a reduction in the number of cross-bridges entering into the force generating cross-bridge cycle. There was no effect of cTnI-S6D on the inhibitory effect of cTnI (Figure 6A), indicating that reaction with the Ip or a second actin binding region may be important in the inhibition of tension. Other evidence also indicates the functional significance of the acidic region of cTnI. Studies [17] have been carried out a on a mutant cTnI truncated by removal of the acidic region (cTnI(Δ2–11)). Compared to controls, hearts of transgenic mice expressing the mutant demonstrated significantly depressed contraction and relaxation kinetics as well as decreased maximal tension in skinned fibers with no influence of the mutation on Ca-sensitivity or phosphorylation at cTnI-S23/S24. Solution NMR studies indicated residues 2–11 do not influence the induction of the open state of cTnC. In contrast to the studies [17] with cTnI(Δ2–11) in which there was no apparent influence of removal of the acidic region on PKA effects on the myofilaments we found that modification at cTnI-S6 suppressed the effect of PKA phosphorylation of cTnI to inhibit activation. Thus, modifications at Ser-6 appear to affect mechanisms by which PKA-dependent phosphorylation of cTnI-S23/S24 suppress response to Ca2+.

Our data indicate a role for cTnI-S6 and cTnI-A2 in modulating the molecular conformation of cTnI and for allosteric interactions with other regions of the cTnI N-terminal peptide. There were significant depressions in tension induced by both Asp and Ala substitutions at cTnI-S6, which indicates conformational changes as well as charge changes influence the function of the cTnI acidic region. The demonstration of significant effects of the conservative substitution of Val for Ala in the DCM linked mutation also indicates the sensitivity of this region to conformational modulation affecting myofilament response to Ca2+ in the form of an altered cooperativity of activation. Moreover the loss of this effect when cTnI-S23/S24 are pseudo-phosphorylated further indicates the allosteric influence of modifications of the acidic region of the cTnI on the phosphorylation motif at S23/S24. Although an obvious limitation to this study is that our control variant (S6A) had similar results to that of our test variant (S6D), there is evidence that Ala substitution is not a silent substitution. In similar studies to those shown here, it was reported that substitution of S23/S24 of cTnI with either Ala or Asp both reduced maximal tension and ATPase activity, due to a decrease in the number of reacting crossbridges [41]. These effects are similar to those demonstrated by another actin-binding protein, calponin [42]. In this case PKC-dependent phosphorylation or Ala substitution at S175 induced the same alteration in affinity of calponin for actin. It is interesting that as with the cTnI-N terminus, calponin is a highly flexible protein, contributing to the idea that alterations in critical structural sites can alter protein function. We think in the case of cTnI conformational modulation of the highly flexible N-terminus provides a mechanism of altered direct and allosteric interactions with neighbors, and in the case of the acidic region with intra-molecular regions of cTnI especially the SwP [15]. Overall our data indicate that modifications at the acidic region may influence diverse functional properties of the myofilaments in a manner not previously appreciated.

Highlights.

  • N-terminus of cardiac troponin I interacts intra-molecularly with regulatory domains

  • We discovered novel phosphorylation sites in the acidic domain

  • Conformation and charge changes affected myofilament Ca-response.

  • A cardiomyopathy linked mutation of Ala-2 to Val affects myofilament activation.

Acknowledgments

The authors thank Chad Warren for excellent advice and technical advice regarding the experiments.

Sources of Funding

This work was supported, in whole or in part, by National Institutes of Health Grants PO1 HL062426 (RJS, PdT), RO1 HL 022231 (RJS), HL 082923 (TK), and HHSN268201000035C (PP). MH and MK were supported by T32 HL 007692, and SBS by F32 HL099029

Non-standard Abbreviations and Acronyms

cTn

cardiac troponin

cTnI

cardiac troponin I

cTnT

cardiac troponin T

cTnC

cardiac troponin C

Tm

tropomyosin

SwP

switch peptide

Ip

inhibitory peptide

Wt

wild type

Footnotes

Disclosures

None

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev. 2000;80:853–924. doi: 10.1152/physrev.2000.80.2.853. [DOI] [PubMed] [Google Scholar]
  • 2.Kobayashi T, Solaro RJ. Calcium, thin filaments, and the integrative biology of cardiac contractility. Physiol Rev. 2005;67:39–67. doi: 10.1146/annurev.physiol.67.040403.114025. [DOI] [PubMed] [Google Scholar]
  • 3.Tripet B, Van Eyk JE, Hodges RS. Mapping of a second actin-tropomyosin and a second troponin C binding site within the C terminus of troponin I, and their importance in the Ca2+-dependent regulation of muscle contraction. J Mol Biol. 1997;271:728–750. doi: 10.1006/jmbi.1997.1200. [DOI] [PubMed] [Google Scholar]
  • 4.Rarick HM, Tu XH, Solaro RJ, Martin AF. The C terminus of cardiac troponin I is essential for full inhibitory activity and Ca2+ sensitivity of rat myofibrils. J Biol Chem. 1997;271:26887–26892. doi: 10.1074/jbc.272.43.26887. [DOI] [PubMed] [Google Scholar]
  • 5.McKay RT, Tripet BP, Pearlstone JR, Smillie LB, Sykes BD. Defining the region of troponin-I that binds to troponin-C. Biochemistry. 1999;38:5478–5489. doi: 10.1021/bi9829736. [DOI] [PubMed] [Google Scholar]
  • 6.Li MX, Spyracopoulos L, Sykes BD. Binding of cardiac troponin-I147–163 induces a structural opening in human cardiac troponin-C. Biochemistry. 1999;38:8289–8298. doi: 10.1021/bi9901679. [DOI] [PubMed] [Google Scholar]
  • 7.Solaro RJ, Rosevear P, Kobayashi T. The unique functions of cardiac troponin I in the control of cardiac muscle contraction and relaxation. Biochem Biophys Res Commun. 2008;369:82–87. doi: 10.1016/j.bbrc.2007.12.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Solaro RJ, Sheehan KA, Lei M, Ke Y. The curious role of sarcomeric proteins in control of diverse processes in cardiac myocytes. J Gen Physiol. 2010;136:13–19. doi: 10.1085/jgp.201010462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Solaro RJ, van der Velden J. Why does troponin I have so many phosphorylation sites? Fact and fancy. J Mol Cell Cardiol. 2010;48:810–816. doi: 10.1016/j.yjmcc.2010.02.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Solaro RJ, Moir AJ, Perry SV. Phosphorylation of troponin I and the inotropic effect of adrenaline in the perfused rabbit heart. Nature. 1976;262:615–617. doi: 10.1038/262615a0. [DOI] [PubMed] [Google Scholar]
  • 11.Solaro RJ. Multiplex kinase signaling modifies cardiac function at the level of sarcomeric proteins. J Biol Chem. 2008;283:26829–26833. doi: 10.1074/jbc.R800037200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Reiffert SU, Jaquet K, Heilmeyer LM, Jr, Ritchie MD, Geeves MA. Bisphosphorylation of cardiac troponin I modulates the Ca(2+)-dependent binding of myosin subfragment S1 to reconstituted thin filaments. FEBS Lett. 1996;384:43–47. doi: 10.1016/0014-5793(96)00274-8. [DOI] [PubMed] [Google Scholar]
  • 13.Schmidtmann A, Lindow C, Villard S, Heuser A, Mugge A, Gessner R, Granier C, Jaquet K. Cardiac troponin C-L29Q, related to hypertrophic cardiomyopathy, hinders the transduction of the protein kinase A dependent phosphorylation signal from cardiac troponin I to C. FEBS J. 2005;272:6087–6097. doi: 10.1111/j.1742-4658.2005.05001.x. [DOI] [PubMed] [Google Scholar]
  • 14.Howarth JW, Meller J, Solaro RJ, Trewhella J, Rosevear PR. Phosphorylation-dependent conformational transition of the cardiac specific N-extension of troponin I in cardiac troponin. J Mol Biol. 2007;373:706–722. doi: 10.1016/j.jmb.2007.08.035. [DOI] [PubMed] [Google Scholar]
  • 15.Warren CM, Kobayashi T, Solaro RJ. Sites of intra- and intermolecular cross-linking of the N-terminal extension of troponin I in human cardiac whole troponin complex. J Biol Chem. 2009;284:14258–14266. doi: 10.1074/jbc.M807621200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Takeda S, Yamashita A, Maeda K, Maeda Y. Structure of the core domain of human cardiac troponin in the Ca(2+)-saturated form. Nature. 2003;424:35–41. doi: 10.1038/nature01780. [DOI] [PubMed] [Google Scholar]
  • 17.Sadayappan S, Finley N, Howarth JW, Osinska H, Klevitsky R, Lorenz JN, Rosevear PR, Robbins J. Role of the acidic N′ region of cardiac troponin I in regulating myocardial function. FASEB J. 2008;22:1246–1257. doi: 10.1096/fj.07-9458com. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Deng Y, Schmidtmann A, Redlich A, Westerdorf B, Jaquet K, Thieleczek R. Effects of phosphorylation and mutation R145G on human cardiac troponin I function. Biochemistry. 2001;48:14593–14602. doi: 10.1021/bi0115232. [DOI] [PubMed] [Google Scholar]
  • 19.Zhang P, Murphy AM, Van Eyk J. Site-specific quantitation of known and novel phosphorylated amino acid residues of cardiac troponin I in human heart failure by multimple reaction monitering. Circulation. 2010;122:A17152. [Google Scholar]
  • 20.Murphy RT, Mogensen J, Shaw A, Kubo T, Hughes S, McKenna WJ. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet. 2004;363:371–372. doi: 10.1016/S0140-6736(04)15468-8. [DOI] [PubMed] [Google Scholar]
  • 21.Goldspink PH, Montgomerhy DE, Walker LA, Urboniene D, McKinney RD, Geenen DL, Solaro RJ, Buttrick PM. Protein kinase Cepsilon overexpression alters myofilament properties and composition during the progression of heart failure. Circ Res. 2004;95:424–432. doi: 10.1161/01.RES.0000138299.85648.92. [DOI] [PubMed] [Google Scholar]
  • 22.Chandra M, Rundell VL, Tardiff JC, Leinwand LA, De Tombe PP, Solaro RJ. Ca(2+) activation of myofilaments from transgenic mouse hearts expressing R92Q mutant cardiac troponin T. Am J Physiol Heart Circ Physiol. 2001;280:H705–H713. doi: 10.1152/ajpheart.2001.280.2.H705. [DOI] [PubMed] [Google Scholar]
  • 23.Kobayashi T, Solaro RJ. Increased Ca2+ affinity of cardiac thin filaments reconstituted with cardiomyopathy-related mutant cardiac troponin I. J Biol Chem. 2006;281:13471–13477. doi: 10.1074/jbc.M509561200. [DOI] [PubMed] [Google Scholar]
  • 24.Sumandea MP, Pyle WG, Kobayashi T, de Tombe PP, Solaro RJ. Identification of a functionally critical protein kinase C phosphorylation residue of cardiac troponin T. J Biol Chem. 2003;278:35135–44. doi: 10.1074/jbc.M306325200. [DOI] [PubMed] [Google Scholar]
  • 25.Takeda S, Kobayashi T, Taniguchi H, Hayashi H, Maeda Y. Structural and functional domains of the troponin complex revealed by limited digestion. Eur J Biochem. 1997;246:611–617. doi: 10.1111/j.1432-1033.1997.00611.x. [DOI] [PubMed] [Google Scholar]
  • 26.Rarick HM, Opgenorth TJ, von Geldern TW, Wu-Wong JR, Solaro RJ. An essential myosin light chain peptide induces supramaximal stimulation of cardiac myofibrillar ATPase activity. J Biol Chem. 1996;271:27039–27043. doi: 10.1074/jbc.271.43.27039. [DOI] [PubMed] [Google Scholar]
  • 27.Scruggs SB, Reisdorph R, Armstrong ML, Warren CM, Reisdorph N, Solaro RJ, Buttrick PM. A novel, in-solution separation of endogenous cardiac sarcomeric proteins and identification of distinct charged variants of regulatory light chain. Mol Cell Prot. 2010;9:1804–1818. doi: 10.1074/mcp.M110.000075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Deng N, Zhang J, Zong C, Wang Y, Lu H, Yang P, Korge P, Lotz C, Doran P, Liem DA, Apweiler R, Weiss JN, Duan H, Ping P. Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Prot. 2011;10:M110.000117. doi: 10.1074/mcp.M110.000117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rundell VL, Manaves V, Martin AF, deTombe PP. Impact of beta-myosin heavy chain isoform expression on cross-bridge cycling kinetics. Am J Physiol (Heart and Circulatory Physiology) 2005;288:H896–H903. doi: 10.1152/ajpheart.00407.2004. [DOI] [PubMed] [Google Scholar]
  • 30.de Tombe PP, ter Keurs HE. Force and velocity of sarcomere shortening in trabeculae from rat heart. Effects of temperature. Circ Res. 1990;66:1239–1254. doi: 10.1161/01.res.66.5.1239. [DOI] [PubMed] [Google Scholar]
  • 31.Brenner B, Eisenberg E. Rate of force generation in muscle: correlation with actomyosin ATPase activity in solution. Proc Natl Acad Sci U S A. 1986;83:3542–3546. doi: 10.1073/pnas.83.10.3542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hinken AC, McDonald KS. Inorganic phosphate speeds loaded shortening in rat skinned cardiac myocytes. Am J Physiol (Cell Physiol) 2004;287:C500–C507. doi: 10.1152/ajpcell.00049.2004. [DOI] [PubMed] [Google Scholar]
  • 33.Kobayashi T, Patrick SE, Kobayashi M. Ala scanning of the inhibitory region of cardiac troponin I. J Biol Chem. 2009;284:20052–20060. doi: 10.1074/jbc.M109.001396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Onishi H, Maeda K, Maeda Y, Inoue A, Fujiwara K. Functional chicken gizzard heavy meromyosin expression in and purification from baculovirus-infected insect cells. Proc Nat Acad Sci (USA) 1995;92:704–708. doi: 10.1073/pnas.92.3.704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Fabiato A. Myoplasmic free calcium concentration reached during the twitch of an intact isolated cardiac cell and during calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned cardiac cell from the adult rat or rabbit ventricle. J Gen Physiol. 1981;78:457–497. doi: 10.1085/jgp.78.5.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Patel JR, Fitzsimons DP, Buck SH, Muthuchamy M, Wieczorek DF, Moss RL. PKA accelerates rate of force development in murine skinned myocardium expressing alpha- or beta-tropomyosin. Am J Physiol (Heart and Circulatory Physiology) 2001;280:H2732–H2739. doi: 10.1152/ajpheart.2001.280.6.H2732. [DOI] [PubMed] [Google Scholar]
  • 37.Wolff MR, McDonald KS, Moss RL. Rate of tension development in cardiac muscle varies with level of activator calcium. Circ Res. 1995;76:154–160. doi: 10.1161/01.res.76.1.154. [DOI] [PubMed] [Google Scholar]
  • 38.Biesiadecki BJ, Kobayashi T, Walker JS, Solaro RJ, de Tombe PP. The troponin C G159D mutation blunts myofilament desensitization induced by troponin I Ser23/24 phosphorylation. Circ Res. 2007;100:1486–1493. doi: 10.1161/01.RES.0000267744.92677.7f. [DOI] [PubMed] [Google Scholar]
  • 39.Burkart EM, Sumandea MP, Kobayashi T, Nili M, Martin AF, Homsher E, Solaro RJ. Phosphorylation or glutamic acid substitution at protein kinase C sites on cardiac troponin I differentially depress myofilament tension and shortening velocity. J Biol Chem. 2003;278:11265–11272. doi: 10.1074/jbc.M210712200. [DOI] [PubMed] [Google Scholar]
  • 40.Noland TA, Jr, Raynor RL, Jideama NM, Guo X, Kazanietz MG, Blumberg PM, Solaro RJ, Kuo JF. Differential regulation of cardiac actomyosin S-1 MgATPase by protein kinase C isozyme-specific phosphorylation of specific sites in cardiac troponin I and its phosphorylation site mutants. Biochemistry. 1996;35:14923–14931. doi: 10.1021/bi9616357. [DOI] [PubMed] [Google Scholar]
  • 41.Mamidi R, Gollapudi SK, Mallampalli SL, Chandra M. Alanine or aspartic acid substitutions at serine 23/24 of cardiac troponin I decrease thin fialment activation, with no effect on crossbridge detachment kinetics. Arch Biochem Biophys. 2012;525:1–8. doi: 10.1016/j.abb.2012.05.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Jin JP, Walsh MP, Sutherland C, Chen W. A role for serine-175 in modulating the molecular conformation of calponin. Biochem J. 2000;350:579–588. [PMC free article] [PubMed] [Google Scholar]

RESOURCES